#USA #Boston #Outcomes4Me #Cancer Care #Jim Longley

Outcomes4Me Welcomes Veteran Health Tech Leader Jim Longley

Outcomes4Me Inc., a trailblazer in cancer care technology, is excited to announce the appointment of Jim Longley as their new Chief Revenue Officer. With a wealth of experience gained from leading companies such as OpenEvidence, GoodRx, and Doximity, Longley will play a vital role in steering the company through its next phase of expansion. His primary mission will be to drive revenue and forge strategic partnerships that benefit patients, healthcare providers, and the pharmaceutical sector.

Longley’s background spans over two decades of leadership within healthcare technology, emphasizing commercial strategies and business development. His impressive track record includes pivotal roles that focused on combining artificial intelligence with healthcare solutions, notably his recent position at OpenEvidence where he sought to innovate through partnerships.

In a statement reflecting on his career shift, Longley expressed his initial intent to take a break from corporate life. However, the potential to make a substantial difference through Outcomes4Me's mission lured him back. He stated, “Outcomes4Me has demonstrated its ability to positively impact cancer patients while also delivering substantial value to pharmaceutical customers by ensuring timely access to their essential therapies. The chance to join an organization where patient welfare is truly a priority is what makes this opportunity unique.” Longley’s enthusiasm highlights the exceptional dedication that Outcomes4Me employs in its operations, fostering an active community of oncology patients eager for new treatment pathways.

The founder and CEO of Outcomes4Me, Dr. Maya R. Said, expressed her excitement about Longley’s arrival, emphasizing his proven ability to cultivate connections that yield mutual benefits across the healthcare landscape. “Jim represents the type of leader we need as we embark on a course for significant growth,” she said. “We are ready for the next chapter, and with Jim's expertise, we are poised for success.”

Outcomes4Me is currently in a dynamic phase of growth, having achieved impressive accolades recently. The company secured a spot on the Inc. 5000 list of the fastest-growing private enterprises in the United States for two consecutive years, with a remarkable growth rate of 395% over the past three years. Additionally, the Fierce family of publications recognized Dr. Said in their 2026 Fierce50 list, an honor that highlights influential figures in the healthcare innovation sector.

Among other milestones, Outcomes4Me has been nominated for the prestigious Prix Galien USA program, which celebrates advancements in medical technology and life sciences. Furthermore, the clinical team successfully integrated ten updates from the National Comprehensive Cancer Network (NCCN) into its platform, ensuring that users have up-to-date information on treatment recommendations for various forms of cancer. It reflects a commitment to equipping patients with the latest treatment options tailored to their specific needs.

Looking ahead, Outcomes4Me will present at the upcoming San Antonio Breast Cancer Symposium, discussing digital tools and patient-reported outcomes in breast cancer at a highlighted session. This presence underscores their proactive stance in improving patient experiences within the oncology space.

In conclusion, Jim Longley’s strategic insights and extensive background in healthcare technology will be pivotal for Outcomes4Me as they continue to innovate and expand their services, significantly impacting the lives of cancer patients and the broader healthcare community. As the company engages with stakeholders at events like Fierce Pharma Week, it is clear that Outcomes4Me is on a path of ambitious growth, with Longley stepping in at a crucial moment to guide their revenue strategies and partnerships for the benefit of all involved parties.

For more information about Outcomes4Me and their services, visit www.outcomes4me.com.